Intensive care medicine · 2002
Hemoglobin-based oxygen carriers do not alter platelet functions: study of three chemically modified hemoglobin solutions.
Сравнительное исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Toussaint Marie, Latger-Cannard Véronique, Caron Alexis, Lecompte Thomas, Vigneron Claude, Menu Patrick
Аннотация
OBJECTIVE: Chemically modified hemoglobins are being developed as potential oxygen-carrying blood substitutes (HBOCs). Clinical and preclinical data demonstrate the vasoactive properties of HBOCs by trapping of nitric oxide, which is also known to have platelet inhibitory activities properties. This study evaluated the effects of three structurally different HBOCs (Hb-Dex-BTC, alphaalpha-Hb, and o-raffinose-poly-Hb) on platelet functions in vitro to compare to those elicited by plasma substitutes, such as hydroxyethylstarch.
DESIGN: Platelet activation state was assessed using platelet-rich plasma diluted to 20% (v/v) with the different solutions, by main measuring glycoproteins (GPIb, GPIIb/IIIa, and P-selectin) using flow cytometry. Aggregation was assessed by impedance aggregometry on whole blood hemodiluted to 20% (v/v) with the solutions.
SETTING: Biological hematology department of the university hospital of Nancy-Brabois.
PATIENTS AND PARTICIPANTS: Ten healthy volunteers consent and informed of the study who denied taking any drugs at the time of the experiment.
MEASUREMENTS AND RESULTS: None of these solutions induced activation nor modified reactivity of platelets as measured by the surface expression of glycoproteins GPIb, GPIIb/IIIa, and P-selectin. Moreover, none of these solutions induced platelet aggregation when added alone, nor modified the aggregation patterns of platelets induced by collagen (0.5 microg/ml) and thrombin receptor agonist peptide (12.5 microM).
CONCLUSIONS: The three tested structurally different HBOCs, as with hydroxyethylstarch, did not alter platelet functions in vitro.
DESIGN: Platelet activation state was assessed using platelet-rich plasma diluted to 20% (v/v) with the different solutions, by main measuring glycoproteins (GPIb, GPIIb/IIIa, and P-selectin) using flow cytometry. Aggregation was assessed by impedance aggregometry on whole blood hemodiluted to 20% (v/v) with the solutions.
SETTING: Biological hematology department of the university hospital of Nancy-Brabois.
PATIENTS AND PARTICIPANTS: Ten healthy volunteers consent and informed of the study who denied taking any drugs at the time of the experiment.
MEASUREMENTS AND RESULTS: None of these solutions induced activation nor modified reactivity of platelets as measured by the surface expression of glycoproteins GPIb, GPIIb/IIIa, and P-selectin. Moreover, none of these solutions induced platelet aggregation when added alone, nor modified the aggregation patterns of platelets induced by collagen (0.5 microg/ml) and thrombin receptor agonist peptide (12.5 microM).
CONCLUSIONS: The three tested structurally different HBOCs, as with hydroxyethylstarch, did not alter platelet functions in vitro.